Esperion Therapeutics Inc. logo

ESPR

Esperion Therapeutics Inc.

$7.06

Earnings Summary

Revenue
$18.84Mn
Net Profits
$-66.32Mn
Net Profit Margins
-352.02%

Highlights

Revenue:

Esperion Therapeutics Inc.’s revenue fell -53.66% since last year same period to $18.84Mn in the Q2 2022. On a quarterly growth basis, Esperion Therapeutics Inc. has generated 0.03% jump in its revenue since last 3-months.

Net Profits:

Esperion Therapeutics Inc.’s net profit fell -51.88% since last year same period to $-66.32Mn in the Q2 2022. On a quarterly growth basis, Esperion Therapeutics Inc. has generated -16.91% fall in its net profits since last 3-months.

Net Profit Margins:

Esperion Therapeutics Inc.’s net profit margin fell -227.76% since last year same period to -352.02% in the Q2 2022. On a quarterly growth basis, Esperion Therapeutics Inc. has generated -16.88% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Esperion Therapeutics Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.91
EPS Estimate Current Year
-0.91

Highlights

EPS Estimate Current Quarter:

Esperion Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.91 - a 2.15% jump from last quarter’s estimates.

EPS Estimate Current Year:

Esperion Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -0.91.

Key Ratios

Key ratios of the Esperion Therapeutics Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
-1.05
Return on Assets (ROA)
-0.41
Return on Equity (ROE)
-2.61
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Esperion Therapeutics Inc.’s earning per share (EPS) jumped 37.13% since last year same period to -1.05 in the Q2 2022. This indicates that the Esperion Therapeutics Inc. has generated 37.13% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Esperion Therapeutics Inc.’s return on assets (ROA) stands at -0.41.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Esperion Therapeutics Inc.’s return on equity (ROE) stands at -2.61.

Dividend Per Share (DPS):

Esperion Therapeutics Inc. declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-03
-1.04
-0.93
10.58%
2022-08-02
-0.93
-1.05
-12.9%

Company Information

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.

Organisation
Esperion Therapeutics Inc.
Headquarters
Ann Arbor, Michigan, US
Employees
479
Industry
Health Technology
CEO
Timothy Mayleben